S1PR2 and carcinoma: Petti L et al. reported that JTE013 treatment broadened high-grade adenomas and carcinomas in an intestinal and mammary tumorigenesis model 35, suggesting that systemic inhibition of S1pr2 might result in a potential oncogenesis.